RE:Quipt to enter diabetes market?From the CC transcript. These boneheads should be disclosing this in news releases. Fire the IR dept.
Our targeted initiatives aimed to drive volume-based growth through enhanced sales efforts, deepened relationships with health care providers and payers and gain access to desired geographic areas. As it relates to cross-selling opportunities, we’re strategically expanding our product offering by entering the diabetes market segment, including CGMs and related supplies. This represents a significant opportunity to enhance our value to our existing patient base. This initiative allows us to address an unmet need within our patient base without necessitating any increase in SG&A expenses. This addition to our portfolio presents a promising avenue for our sales team to cross-sell new products, leveraging their established relationships and familiarity with the needs of our patients.